Oral idarubicin in the treatment of acut
β
S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister
π
Article
π
1989
π
John Wiley and Sons
π
English
β 307 KB
Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per